Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial

NCT03509688 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT03509688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03509688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial
Lead sponsor
The First Hospital of Jilin University
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2014
Completion date
December 31, 2017
Enrollment
312 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis